[1]李　辉,汪春新,秦明明,等.肺癌患者血清7项肿瘤标志物联合检测在病理分型及临床分期中的应用价值研究[J].现代检验医学杂志,2021,36(04):5-9.[doi:10.3969/j.issn.1671-7414.2021.04.002]
　LI Hui,WANG Chun-xin,QIN Ming-ming,et al.Study on the Application Value of Combined Detection of 7 Tumor Markersin Serum of Patients with Lung Cancer in Pathological Classificationand Clinical Staging[J].Journal of Modern Laboratory Medicine,2021,36(04):5-9.[doi:10.3969/j.issn.1671-7414.2021.04.002]
点击复制

肺癌患者血清7项肿瘤标志物联合检测在病理分型及临床分期中的应用价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第36卷
期数:
2021年04期
页码:
5-9
栏目:
论　著
出版日期:
2021-07-31

文章信息/Info

Title:
Study on the Application Value of Combined Detection of 7 Tumor Markersin Serum of Patients with Lung Cancer in Pathological Classificationand Clinical Staging
文章编号:
1671-7414（2021）04-005-06
作者:
李　辉1; 汪春新1; 秦明明1; 王　婧1; 许义侠1; 顾云侠1; 陈礼文2
（1. 安徽医科大学附属阜阳医院检验科，安徽阜阳 236000； 2. 安徽医科大学第二附属医院，合肥 230601）
Author(s):
LI Hui1;  WANG Chun-xin1; QIN Ming-ming1;  WANG Jing1;  XU Yi-xia1;  GU Yun-xia1;  Chen Li-wen2
（1.Department of Clinical Laboratory, Fuyang Hospital Affiliated to Anhui Medical University, Anhui Fuyang 236000, China;2.Department of Clinical Laboratory, the Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China）
关键词:
肺癌; 肿瘤标志物; 病理分型; 临床分期
分类号:
R734.2；R730.43
DOI:
10.3969/j.issn.1671-7414.2021.04.002
文献标志码:
A
摘要:
目的　探讨癌胚抗原（carcinoembryonic antigen, CEA）、细胞角蛋白19 片段（cytokeratin 19 fragment,CYFRA21-1）、神经元特异性烯醇化酶（neuron-specific enolase, NSE）、胃泌素释放肽前体（gastrin-releasing peptideprecursor, ProGRP）、鳞状细胞癌抗原（squamous cell carcinoma antigen, SCC）、糖类抗原125（carbohydrate antigen125, CA125）和人附睾分泌蛋白4（human epididymis secrete protein 4, HE4）等7 项肿瘤标志物单项或联合检测对肺癌诊断、病理分型及临床分期的应用价值。方法　以41 例健康体检者和40 例肺良性疾病患者为对照，采用电化学发光法检测88 例肺癌患者血清CEA，CYFRA21-1，NSE，ProGRP，SCC，CA125 和HE4 水平，采用非参数检验、卡方检验及ROC 曲线比较7 项指标单独或联合检测的临床价值。 结果　肺癌患者血清7 项肿瘤标志物水平均高于肺良性疾病组和健康体检组，差异均有统计学意义（H=9.940~64.275, 均P<0.01）；肺腺癌患者CEA 水平及阳性率均高于鳞癌和小细胞肺癌患者（χ2=16.00，P=0.000；H=12.708，P=0.002），肺鳞癌患者SCC 水平及阳性率均高于腺癌和小细胞肺癌患者（χ2=42.102，P=0.000；H=37.525，P=0.000），小细胞肺癌患者NSE，ProGRP，CA125 和HE4 水平及阳性率均高于鳞癌患者，而NSE 和ProGRP 水平及阳性率均高于腺癌患者，差异均有统计学意义（H=7.223~32.895，χ2=6.213~49.491,均P<0.05）；肺癌Ⅳ期患者CA125 和HE4 水平高于Ⅰ + Ⅱ期和Ⅲ期患者，CEA，CYFRA21-1 和NSE 水平高于Ⅰ + Ⅱ期患者，差异均有统计学意义（H=7.678~26.918, 均P<0.05）；诊断肺癌（总体）、肺腺癌、肺鳞癌和小细胞肺癌曲线下面积（AUC）最大的项目分别为CYFRA21-1 (0.823)，CEA (0.816)，SCC (0.947) 和NSE(0.957)，7 项联合检测诊断肺癌（总体）、肺腺癌、肺鳞癌和小细胞肺癌的AUC 分别为0.855，0.849，0.864 和0.983。 结论　肿瘤标志物CEA，SCC，NSE，ProGRP，CA125 和HE4 水平对肺癌分型有一定临床应用价值，而CYFRA21-1，CEA，SCC 和NSE 水平对肺癌分期有一定临床应用价值，7 项联合检测诊断肺癌（总体）、肺腺癌和小细胞肺癌优于单项检测。

参考文献/References:

[1] BACHNER F, BOBEK J, HABIMANA K, et al.Austria: Health system review[J]. Health Syst Transit.2018. 20(3): 1-254.
[2] 敖素华，杨峰．血清多项肿瘤标志物联合检测在肺癌诊断中的价值[J]. 重庆医学,2013,42(31):3764-3765.AO Suhua, YANG Feng. Clinical significance ofmultiple serum tumor markers combined detectionin the diagnosis of lung cancer[J].ChongqingMedicine,2013, 42(31):3764-3765.
[3] 吴晓燕，朱自力，张金业，等. 肿瘤标志物检测在肺癌诊断中的临床应用价值探讨[J]. 检验医学,2014,29(5):578-580.WU Xiaoyan, ZHU Zili, ZHANG Jinye, et al.Discussionon the clinical application value of tumor markerdetection in the diagnosis of lung cancer[J].LaboratoryMedicine,2014,29(5):578-580.
[4] 中华人民共和国国家卫生健康委员会.WS/T 459-2018: 常用血清肿瘤标志物检测的临床应用和质量管理 WS/T 459[S]. 北京：中国标准出版社,2018.National Health Commission of the PRC. WS/T 459-2018 Common used serum tumor marker tests: clinicalpractice and quality management[S]. Beijing: StandardsPress of China,2018.
[5] 支修益, 石远凯, 于金明. 中国原发性肺癌诊疗规范(2015 年版)[J]. 中华肿瘤杂志,2015,37(1)：37-77.ZHI Xiuyi, SHI Yuankai, YU Jinming. Chinese lungcancer treatment guidelines (2015 edition)[J].ChineseJournal of Oncology,2015,37(1)：67-68.
[6] LI Yong, LI Xiaohui, SHI Gongning, et al. Applicationvalue of joint detection of serum marker CYFRA21-1，NSE，CEA，CA19-9，CA125，SCC in diagnosisof lung cancer[J]. Acta Medica Mediterranea,2016,32(1):1671-1674.
[7] MOLINA R, MARRADES R M, AUG? J M, et al.Assessment of a combined panel of six serum tumormarkers for lung cancer[J]. Am J Respir Crit CareMed,2016,193(4):427-437.
[8] GENET S, VISSER E, VAN DEN BORNE B, et al.Correction of the NSE concentration in hemolyzedserum samples improves its diagnostic accuracy insmall-cell lung cancer[J]. Oncotarget. 2020. 11(27):2660-2668.
[9] CHOI SI, JANG M A, JEON B R, et al. Clinicalusefulness of human epididymis protein 4 in lungcancer[J]. Ann Lab Med,2017,37(6):526-530.
[10] 季红兵, 唐芹芳, 陈思聪, 等. 血清肿瘤标志物HE4对肺癌的诊断价值[J]. 现代检验医学杂志, 2017, 32(2):110-113.JI Hongbin, TANG Qinfang, CHEN Sicong, et al.Application of serum HE4 in the diagnosis of lungcancer[J]. Journal of Modern Laboratory Medicine,2017,32(2):110-113.
[11] 张萍, 王红义, 杨迎桂. 血清CEA,ProGRP,NSE 和CYFRA21-1 联合检测在肺癌诊断中的应用研究[J].现代检验医学杂志,2016,31(2):56-59.ZHANG Ping, WANG Hongyi, YANG Yingguai,et al. Clinical application of combined detection ofCEA,ProGRP,NSE and CYFRA21-1 in diagnosis oflung cancer[J]. Journal of Modern Laboratory Medicine,2016,31(2):56-59.
[12] 赵车冬, 闫玉珠, 吴文婧, 等. 血清CEA,CYFRA21-1 和NSE 水平在肺癌诊断与分型中的应用价值[J]. 现代检验医学杂志,2016,31(6):59-61,65.ZHAO Chedong, YAN Yuzhu, WU Wenjing, et al.Application value of serum CEA, CYFRA21-1 and NSElevels in the diagnosis and typing of lung cancer[J].Journal of Modern Laboratory Medicine,2016,31(6)：59-61,65.
[13] 彭瑛，邓正华，温先勇. 国内13 种肿瘤标志物对肺癌诊断价值的Meta 分析[J]. 现代检验医学杂志,2016,31(1):96-100.PENG Ying, DENG Zhenghua, WEN Xianyong, etal. Diagnostic value of thirteen types of serum tumormarkers for lung cancer in China, A meta analysis[J].Journal of Modern Laboratory Medicine,2016,31(1)：96-100.
[14] 吴园园, 管世鹤, 杨凯, 等. 血清肿瘤标志物在肺癌辅助诊断中的应用[J]. 中国微生态学杂志,2017,29(5)：547-549.WU Yuanyuan, GUAN Shihe, YANG Kai, et al. Thevalue of serum tumor markers in the diagnosis of lungcancer[J].Chinese Journal of Microecology, 2017, 29(5):547-549.
[15] DONG Aoran, ZHANG Jiali, CHEN Xiaobin, et al.Diagnostic value of ProGRP for small cell lung cancer indifferent stages[J]. J Thorac Dis, 2019, 11(4): 1182-1189.
[16] 孙红梅，陈文彰，燕丽香，等. 4 种肿瘤标志物在肺癌病理分型、分期中的临床价值[J]. 现代肿瘤医学,2014,22(9)：2105-2109.SUN Hongmei, CHEN Wenzhang, YAN Lixiang, etal. Clinical value of four serum tumor markers inpathology type and stage of lung cancer[J]. Journal ofModern Oncology,2014,22(9):2105-2109.
[17] 武彩虹，钱成荣，韩玉成，等. CEA，SCC-Ag，NSE 及SE-CAD 在肺癌病理分型、分期中的临床价值[J]. 中国实验诊断学,2016,20(2):240-243.WU Caihong, QIAN Chengrong, HAN Yucheng, et al.Clinical value of CEA, SCC-AG, NSE and SE-CADin pathology type and stage of lung cancer[J].ChineseJournal of Laboratory Diagnosis, 2016,20(2):240-243.

相似文献/References:

[1]马丽颜,梁 静,周建龙.腺瘤样结肠息肉易感基因(APC)及结直肠癌缺失基因(DCC)基因甲基化在肺癌早期诊断的意义[J].现代检验医学杂志,2016,31(01):17.[doi:10.3969/j.issn.1671-7414.2016.01.005]
　MA Li-yan,LIANG Jing,ZHOU Jian-long.Evaluation of the Combination of APC and DCC Gene Methylation in the Early Diagnosis of Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(04):17.[doi:10.3969/j.issn.1671-7414.2016.01.005]
[2]彭 瑛,邓正华,温先勇.国内13种血清肿瘤标志物对肺癌诊断价值的Meta分析[J].现代检验医学杂志,2016,31(01):96.[doi:10.3969/j.issn.1671-7414.2016.01.028]
　PENG Ying,DENG Zheng-hua,WEN Xian-yong.Diagnostic Value of Thirteen Types of Serum Tumor Markers for Lung Cancer in China:A Meta-Analysis[J].Journal of Modern Laboratory Medicine,2016,31(04):96.[doi:10.3969/j.issn.1671-7414.2016.01.028]
[3]王红梅,陈晔洲,田晶晶,等.新型肿瘤标志物人PF4重组表达、活性鉴定及单克隆抗体制备[J].现代检验医学杂志,2015,30(05):12.[doi:10.3969/j.issn.1671-7414.2015.05.005]
　WANG Hong-mei,CHEN Ye-zhou,TIAN Jing-jing,et al.Recombination，Expression，Activity Identification and Monoclonal Antibody Preparation of the Human Platelet Factor 4 as a New Cancer Marker[J].Journal of Modern Laboratory Medicine,2015,30(04):12.[doi:10.3969/j.issn.1671-7414.2015.05.005]
[4]余安运,陶丹,刘夏炎,等.肿瘤标志物在消化系统肿瘤早期诊断中的应用[J].现代检验医学杂志,2015,30(06):133.[doi:10.3969/j.issn.1671-7414.2015.06.041]
　YU An-yun,TAO Dan,LIU Xia-yan,et al.Clinical Value of Blood Serums Tumor Marker in Early Diagnosis of Digestive System Neoplasms[J].Journal of Modern Laboratory Medicine,2015,30(04):133.[doi:10.3969/j.issn.1671-7414.2015.06.041]
[5]翟海军,朱晶.红细胞分布宽度对肺癌预后的临床分析[J].现代检验医学杂志,2015,30(06):147.[doi:10.3969/j.issn.1671-7414.2015.06.045]
　ZHAI Hai-jun,ZHU Jing.Clinical Analysis of Red Blood Cell Distribution Width on the Prognosis of Lung Cancer[J].Journal of Modern Laboratory Medicine,2015,30(04):147.[doi:10.3969/j.issn.1671-7414.2015.06.045]
[6]姜 波,王玉明,段 勇.肺癌组织中调控PUMA基因 的miRNA筛查和MiR-221表达差异研究[J].现代检验医学杂志,2015,30(01):15.[doi:10.3969/j.issn.1671-7414.2015.01.005]
　JIANG Bo,WANG Yu-ming,DUAN Yong.Study on the Differential Expression of miRNA Screening and MiR-221 Regulates Apoptosis by Targeting PUMA Gene in Lung Cancer[J].Journal of Modern Laboratory Medicine,2015,30(04):15.[doi:10.3969/j.issn.1671-7414.2015.01.005]
[7]赵车冬,闫玉珠,吴文婧,等.血清CEA,CYFRA21-1,NSE水平在肺癌诊断与分型中的应用价值[J].现代检验医学杂志,2016,31(06):59.[doi:10.3969/j.issn.1671-7414.2016.06.016]
　ZHAO Che-dong,YAN Yu-zhu,WU Wen-jing,et al.Application Value of Serum CEA,CYFRA21-1 and NSE Levels in the Diagnosis and Typing of Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(04):59.[doi:10.3969/j.issn.1671-7414.2016.06.016]
[8]董 莉,张保平,冯新平,等.血浆HSP90α检测在肺癌诊断中的临床应用价值研究[J].现代检验医学杂志,2017,32(04):97.[doi:10.3969/j.issn.1671-7414.2017.04.027]
　DONG Li,ZHANG Bao-ping,FENG Xin-ping,et al.Plasma HSP90 Alpha Testing Clinical Application Value in the Diagnosis of Lung Cancer Researc[J].Journal of Modern Laboratory Medicine,2017,32(04):97.[doi:10.3969/j.issn.1671-7414.2017.04.027]
[9]万 军.血清肿瘤标志物CA153,CA125,CEA和HER-2联合检测在乳腺癌诊断中的价值[J].现代检验医学杂志,2018,33(06):119.[doi:10.3969/j.issn.1671-7414.2018.06.031]
　WAN Jun.Value of Combined Detection of Tumor Markers CA153,CA125,CEA and HER-2 in the Diagnosis of Breast Cancer[J].Journal of Modern Laboratory Medicine,2018,33(04):119.[doi:10.3969/j.issn.1671-7414.2018.06.031]
[10]张利祥,潘 静,赵 洁,等.痰液基细胞学检查与血清CYFRA21-1,CEA,NSE联合检测对肺癌的诊断价值[J].现代检验医学杂志,2019,34(03):99.[doi:10.3969/j.issn.1671-7414.2019.03.024]
　ZHANG Li-xiang,PAN Jing,ZHAO Jie,et al.Value of the Combined Determination of Sputum Liquid-Based Cytologyand Serum CYFRA21-1,CEA,NSE for the Diagnosis of Lung Cancer[J].Journal of Modern Laboratory Medicine,2019,34(04):99.[doi:10.3969/j.issn.1671-7414.2019.03.024]

备注/Memo

备注/Memo:
基金项目：安徽省科技厅重点研发项目（202004j07020027）。
作者简介：李辉（1985-），男，硕士研究生，主管技师，主要从事临床免疫学检验工作，E-mail:263779323@qq.com。
通讯作者：陈礼文（1973-），男，博士，主任技师，硕士生导师，主要从事临床免疫学方面研究，E-mail:lw_ch@163.com。
更新日期/Last Update: 2017-12-31